Teva Pharmaceutical Industries CEO Says Just-Launched Schizophrenia Drug Weltruza Won't See Significant Revenue Until Second Half Of 2027, In Good Position For 2028; Despite Growth In Branded Drugs, Generics To Continue To Grow And Be Profitable Due To Biosimilars Pipeline; Co. Aims To Grow In 2027 Despite U.S. Inflation Reduction Act Impact On Its Austedo Drug

Benzinga · 3d ago

-Conference Call.